You are viewing a free preview of this lesson.
Subscribe to unlock all 10 lessons in this course and every other course on LearningBro.
Drug therapy (pharmacotherapy) is the most widely used biological treatment for schizophrenia and is usually the first-line intervention. It follows directly from the dopamine hypothesis: if abnormal dopamine activity underlies symptoms, then drugs that act on the dopamine system should relieve them. There are two main classes of antipsychotic medication — typical (first-generation) antipsychotics and atypical (second-generation) antipsychotics — and the development of the second class was driven largely by the need to reduce the serious side effects of the first. This lesson examines their mechanisms, their effectiveness and the practical and ethical issues that surround their use, all discussed in the measured, clinical register appropriate to this topic.
Key Definition: Antipsychotic drugs are medications used to manage psychotic symptoms such as hallucinations and delusions. They work primarily by reducing the action of the neurotransmitter dopamine at its receptors in the brain.
This lesson covers drug therapy for schizophrenia as named in the AQA 7182 Paper 3 option: typical and atypical antipsychotics. You must be able to describe the mechanism of typical antipsychotics (dopamine antagonism, with chlorpromazine as the key example) and of atypical antipsychotics (action on dopamine and serotonin receptors, with clozapine and risperidone as examples), and to discuss their effectiveness and side effects. You must then evaluate drug therapy as AO3, including the evidence on relapse and response rates, the appropriateness of the dopamine rationale, the serious side-effect burden, the problem of adherence, and ethical concerns such as consent and the use of medication as a means of control. The specification also expects awareness that drug therapy is typically combined with psychological therapies (Lesson 5), so this lesson links forward to the interactionist treatment model.
Typical antipsychotics were the first class of antipsychotic drug, introduced in the 1950s, and they revolutionised the care of people with schizophrenia by making it possible to manage acute symptoms outside long-stay institutions. The standard example is chlorpromazine.
Typical antipsychotics are dopamine D2 receptor antagonists: they bind to D2 receptors and block them, preventing dopamine from acting on the post-synaptic neuron. By reducing dopaminergic transmission in subcortical (mesolimbic) regions, they relieve the positive symptoms of hallucinations and delusions — exactly as the dopamine hypothesis predicts. The sequence can be summarised as follows:
Chlorpromazine also has marked sedative effects, partly through its action on histamine receptors. This is clinically useful for calming a person who is highly distressed or agitated during an acute episode, and historically it was often used for this purpose — a fact that becomes important when we evaluate the ethics of "chemical restraint" below.
A defining problem of the typical antipsychotics is that they block D2 receptors throughout the brain, not only where this is therapeutic. Blockade in the nigrostriatal pathway (which controls movement) and the tuberoinfundibular pathway (which regulates prolactin) produces a range of significant side effects:
| Side Effect | Description |
|---|---|
| Extrapyramidal symptoms (EPS) | Movement disturbances including tremor, rigidity and restlessness, caused by D2 blockade in the nigrostriatal pathway |
| Tardive dyskinesia | Involuntary, repetitive movements of the face, tongue and jaw, developing after prolonged use and sometimes irreversible |
| Sedation | Drowsiness and lethargy, partly from antihistamine action |
| Weight gain | Common, with implications for long-term physical health |
| Neuroleptic malignant syndrome (NMS) | A rare but potentially fatal reaction involving high fever, muscle rigidity and altered consciousness |
| Raised prolactin | From D2 blockade in the tuberoinfundibular pathway, leading to hormonal and sexual side effects |
Key Definition: Tardive dyskinesia is a potentially irreversible movement disorder caused by long-term use of (especially typical) antipsychotics, characterised by involuntary movements of the face, tongue and limbs, and resulting from chronic D2 blockade in the nigrostriatal pathway.
Exam Tip: Always mention tardive dyskinesia and EPS when evaluating typical antipsychotics. The severity and irreversibility of these motor side effects is the single most important reason the atypical antipsychotics were developed — so the two classes are best evaluated by comparison.
Atypical (second-generation) antipsychotics were introduced from the 1970s and into widespread use through the 1990s, specifically to retain effectiveness against positive symptoms while reducing the motor side effects (EPS, tardive dyskinesia) of the typical drugs, and ideally to improve negative symptoms as well. The two examples named at A-Level are clozapine and risperidone.
Clozapine is regarded as the most effective antipsychotic, particularly for treatment-resistant schizophrenia — that is, for people who have not responded adequately to at least two other antipsychotics.
Mechanism of action. Clozapine acts on multiple receptor systems. It is a dopamine-serotonin antagonist, blocking both D2 dopamine receptors and 5-HT2A serotonin receptors, and it also acts on noradrenergic, histaminergic and cholinergic receptors. Importantly, it binds to D2 receptors more loosely and transiently than typical antipsychotics, which is thought to underlie its much lower rate of EPS. By acting on serotonin receptors it can increase dopamine release in the prefrontal cortex, which may help relieve negative symptoms and cognitive impairment — addressing the hypodopaminergia component of the revised dopamine hypothesis.
Effectiveness. Kane et al. (1988) compared clozapine with chlorpromazine in 268 treatment-resistant patients; after six weeks, around 30% of the clozapine group showed meaningful improvement, against about 4% on chlorpromazine. Clozapine has also been associated with reduced suicidality and improved social functioning and quality of life, which is why it remains in use despite its risks.
Risks. Clozapine's most serious side effect is agranulocytosis, a dangerous fall in white blood cell count that can be life-threatening. For this reason its use requires regular blood monitoring (frequent at first, then less often), and patients are enrolled in a monitoring scheme. Other side effects include weight gain, metabolic disturbance and excessive salivation. The blood-monitoring requirement is the principal reason clozapine is reserved for treatment-resistant cases rather than used first.
Risperidone is a widely prescribed atypical antipsychotic, developed in part to provide an effective drug that could be used in smaller doses and was generally better tolerated than clozapine.
Mechanism of action. Like clozapine, risperidone blocks both D2 and 5-HT2A receptors, but it binds more tightly to D2 receptors than clozapine does (though typically less than the older typical drugs). The combined dopamine-serotonin action is intended to control positive symptoms while limiting EPS.
Effectiveness and side effects. Risperidone is effective against positive and, to some extent, negative symptoms. It does not carry clozapine's risk of agranulocytosis, so it does not require blood monitoring. However, at higher doses it can still produce EPS, and it commonly causes weight gain and raised prolactin.
Key Definition: Atypical antipsychotics are second-generation medications that act on both dopamine D2 receptors and serotonin 5-HT2A receptors. They were designed to reduce the motor side effects associated with typical antipsychotics.
| Feature | Typical (e.g. chlorpromazine) | Atypical (e.g. clozapine, risperidone) |
|---|---|---|
| Primary mechanism | D2 receptor antagonist | Dopamine-serotonin antagonist |
| Positive symptoms | Effective | Effective |
| Negative symptoms | Limited | Better (especially clozapine) |
| EPS / tardive dyskinesia | Higher risk | Lower risk |
| Agranulocytosis | Very rare | A specific risk with clozapine |
| Blood monitoring | Not required | Required for clozapine |
| Typical clinical role | First-generation, broadly used historically | Often preferred now; clozapine reserved for treatment resistance |
Because "effectiveness" is the most heavily examined aspect of drug therapy, it is worth setting out the principal evidence explicitly. Effectiveness is established by controlled comparison, typically against a placebo, and is summarised in meta-analyses that pool many trials.
| Evidence | Design | Key finding | Evaluative use |
|---|---|---|---|
| Davis et al. (1980) | Meta-analysis vs placebo | Relapse much higher on placebo than medication | Strong support for effectiveness against relapse |
| Kane et al. (1988) | RCT, treatment-resistant patients | Clozapine markedly outperformed chlorpromazine | Clozapine effective where other drugs fail |
| Leucht et al. (2012) | Meta-analysis, thousands of patients | Meaningful improvement in ~half; relapse reduced | Effectiveness is real but only partial |
The honest summary is that antipsychotics are clearly more effective than placebo, particularly for positive symptoms and relapse prevention, but that their effect is partial — incomplete for many patients and weak against negative symptoms. This balanced reading is what a strong evaluation requires.
A drug that is effective in a trial achieves nothing if it is not taken, and non-adherence is one of the leading causes of relapse. Adherence is undermined by unpleasant side effects (sedation, weight gain, sexual dysfunction), by the reduced insight that is itself a feature of the disorder, and by the understandable tendency to stop medication once a person feels well. To address this, longer-acting "depot" preparations have been developed: instead of daily tablets, the drug is given as a slow-release injection every few weeks. Depot medication can improve adherence and reduce relapse, though — as the evaluation notes — it also sharpens the ethical question of how far treatment should be made difficult to discontinue.
Drug therapy for schizophrenia connects to several wider areas of the specification:
There is strong meta-analytic evidence that antipsychotics are effective in reducing symptoms and preventing relapse. Reviews comparing antipsychotics with placebo consistently find lower relapse and greater symptom improvement on medication; for example, large pooled analyses report that a substantial proportion of patients achieve clinically meaningful improvement on antipsychotics, and that relapse is markedly higher on placebo. This matters because it establishes, with controlled evidence rather than clinical impression, that the drugs do more than sedate — they reduce the core symptoms. The implication is that drug therapy has a justified place as a first-line treatment, even granting the serious limitations below.
However, effectiveness is partial, and a large minority of patients do not respond adequately. The same evidence base shows that a considerable proportion of patients gain little benefit, and that negative symptoms in particular respond poorly to the typical drugs. This matters because it tempers the "drugs work" conclusion: for many people, medication controls positive symptoms incompletely and leaves the disabling negative and cognitive symptoms largely untouched. The implication is that drug therapy alone is insufficient for a large group of patients, which is part of the rationale for combining it with psychological therapy.
The success of dopamine-antagonist drugs supports the dopamine hypothesis, but the inference must be made carefully. That D2-blocking drugs relieve positive symptoms is genuine support for a dopaminergic account of those symptoms. However, treatment effectiveness does not straightforwardly prove the causal theory: the delayed clinical response (symptoms improve over weeks though receptors are blocked within hours) suggests the therapeutic mechanism is more complex than simple dopamine reduction, and the role of glutamate (Lesson 2) indicates dopamine is not the whole story. The implication is that the drugs' success is consistent with the dopamine hypothesis without confirming it in full, and over-claiming here is a common evaluative error.
Subscribe to continue reading
Get full access to this lesson and all 10 lessons in this course.